-Groundbreaking AI-enabled diagnosis technology is able to detect over 30 medical conditions with high-level accuracy including strokes, Alzheimer’s, Thyroids cancer, Breast cancer, and Joint disease
CHICAGO, Nov. 16, 2018 /PRNewswire/ — This month JLK Inspection will participate in the Radiological Society of North America (RSNA) 2018 in Chicago, presenting its latest AI-based medical image diagnosis system.
The company’s technology assists medical practitioners with detecting and monitoring more than 30 medical conditions, including strokes, Alzheimer’s, prostate cancer, lung cancer thyroids cancer, breast cancer, and joint disease. JLK’s AI-enabled image analysis include those conducted in MRI, CT, X-ray and mammography format, with its technology casting a wide net over various diagnostic techniques.
“We look forward to demonstrating our medical imaging system at RSNA,” JLK Inspection CEO Won Tae Kim says. “We are excited to show how we are able to assist users with quantitative analysis of their medical images at their own convenience.”
These include neural network solvers and libraries with an on-site AI platform providing a real time, seamless connection through a user-friendly interface. This also means the JLK system is stable and interlocks with all other in-hospital systems. They also provide state-of-the-art multi-contrast MRI and multi-modality images.
Not only are JLK’s products created to be simple to use, but they provide objectivity of medical care based on quantitative AI analysis in a streamlined, easy-to-analyze format. For this, JLK Inspection has also developed an AI medical all-in-one platform called AI HUB.
This month, JLK will debut the JBS-01K at RSNA 2018 which already received approval from the Korean FDA as a class III device. The system analyzes brain MRI images and clinical information to detect and present results of ischemic stroke diagnosis for users. The company’s newest medical solution for stroke diagnosis is already in the process of gaining FDA and CE approvals in the U.S. and Europe, respectively.
As a multi-diagnosis solution, the JPC-01K also aims at detecting and diagnosing prostate cancer by automatically detecting the exact location of the cancer, then providing the user with a rapid response and prompt diagnosis. Furthermore, the JPC-01K will also give medical professionals the ability to perform an MR-targeted biopsy while helping reduce risks such as injection, pain, etc.
As a testament to its goals and efforts, JLK has raised over $17M in VC funding to date. The company has also worked hard to ensure numerous patents for their technology have been registered.
The imaging solutions company is planning on going public in the near future, with a set IPO on the KOSDAQ in the second half of 2019. Part of JLK’s current global operations include marketing offices in Silicon Valley and R&D and manufacturing facilities in Seoul, ROK.
Along with heading to RSNA this month, taking place from November 25-30, JLK Inspection will also be present at the International Security Expo (ISE) in London, UK from November 28-29. The company will be attending the conference on behalf of their imaging technology JSS-01K, a security solution that detects storage devices (USB, smartphone, external hdd, and tablet pcs) in security x-ray images.
About JLK Inspection Inc.
JLK Inspection is a Seoul, South Korea-based medical solutions provider specializing in AI-based technology. JLK Inspection is a member company of the K-ICT Born2Global Centre. JLK Inspection’s universal AI platform is created by a combination of big data, experts, and our own unique engines & algorithms. It provides the on-site/real-time service that is seamlessly connected to all systems.
View original content to download multimedia:http://www.prnewswire.com/news-releases/jlk-inspection-to-showcase-its-ai-based-medical-solutions-at-rsna-300752020.html